BridgeBio Pharma, Inc. (BBIO)

28,85 +1,24 (+4,49%) Al cierre: 04:00PM EDT

BridgeBio Pharma, Inc.

3160 Porter Drive
Suite 250
Palo Alto, CA 94304
United States
650 391 9740
https://bridgebio.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 550

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Neil Kumar Ph.D.	Co-Founder, President, CEO & Director	1,53M	N/A	1979
Dr. Charles J. Homcy M.D.	Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director	563,2k	N/A	1948
Dr. Frank P. McCormick Ph.D.	Co-Founder, Chairman of Oncology & Director	542,78k	N/A	1950
Dr. Brian C. Stephenson C.F.A., Ph.D.	CFO & Secretary	1,15M	N/A	1981
Dr. Richard H. Scheller Ph.D.	Chairman of Research & Development	509,62k	N/A	1953
Dr. Uma Sinha Ph.D.	Chief Scientific Officer	1,31M	N/A	1958
Grace Rauh	Vice President of Communications	N/A	N/A	N/A
Mr. Eli M. Wallace Ph.D.	Chief Scientific Officer of Oncology	N/A	N/A	1967
Dr. Thomas Trimarchi Ph.D.	Chief Product Officer	N/A	N/A	N/A
Dr. Eric Michael David J.D., M.D., Ph.D.	Chief Executive Officer of Gene Therapy	N/A	N/A	1972

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Gobierno corporativo

El ISS Governance QualityScore de BridgeBio Pharma, Inc., a día 29 de mayo de 2024, es 10. Las puntuaciones base son Auditoría: 3; Tablero: 10; Derechos de los accionistas: 8; Compensación: 10.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.